SEROCO: COVID-19 Serological Status of Hospital Staff Working or Not in the COVID-19 Sector

Sponsor
University Hospital, Limoges (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT04481529
Collaborator
(none)
1,576
4
5.6
394
70.5

Study Details

Study Description

Brief Summary

Hospital staff, on the front line in the COVID-19 crisis, have many questions about the risk that they have been infected with this potentially fatal virus. These questions of course primarily concern caregivers working in sectors dedicated to COVID-19 patients, whether they are resuscitating or not, but also those in non-COVID-19 sectors, or even staff without direct contact with patients. In addition, depending on the suddenness and intensity of this "COVID-19 wave", these personnel have been more or less trained and sometimes exposed due to the dire lack of protective equipment. In some countries such as Great Britain, this has resulted in significant absenteeism, a source of deepening the shortage of caregivers.

This proportion of contaminated caregivers has not been evaluated on the whole of French territory. Studies from other countries suggest figures ranging from 1.5% in China to 20% in Italy. It is therefore impossible to rely on such variable data to have a reliable estimate.

Since june 2020, all staff in French health establishments could benefit a serological test.

Thus, in this epidemiological study, we propose to rely on this institutional serological screening to describe the link between seroconversion of hospital staff, regional intensity of the epidemic, and sectors of activity (COVID-19 sectors, non-COVID-19 caregivers , non-COVID-19 non-caregivers.

Condition or Disease Intervention/Treatment Phase
  • Other: Health Questionnaire

Study Design

Study Type:
Observational
Actual Enrollment :
1576 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Study of the COVID-19 Serological Status of Hospital Staff Working or Not in the COVID-19 Sector in 3 French Regions Facing the COVID-19 Epidemic With Varying Degrees of Intensity
Actual Study Start Date :
Jul 29, 2020
Actual Primary Completion Date :
Dec 15, 2020
Anticipated Study Completion Date :
Jan 15, 2021

Outcome Measures

Primary Outcome Measures

  1. Number of subjects with a COVID-19 seroconversion [through study completion, an average of 5 month]

    Number of subjects with a COVID-19 seroconversion fixed by the presence of IgG + in serology according to the service (COVID19 +, COVID19- caregiver, COVID- non-caregiver).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Hospital staff from Argenteuil, Belfort, Dijon and Limoges hospitals.

  • Age ≥ 18 years old

  • Participation agreement

Exclusion Criteria:
  • Protected persons

  • Refusal of participation

Contacts and Locations

Locations

Site City State Country Postal Code
1 CH Argenteuil - Service de Réanimation Argenteuil France 95107
2 Ch Belfort Belfort France 90000
3 CHU Dijon - Serve de Réanimation Dijon France 21079
4 CHU de Limoges Limoges France

Sponsors and Collaborators

  • University Hospital, Limoges

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Limoges
ClinicalTrials.gov Identifier:
NCT04481529
Other Study ID Numbers:
  • 87RI20_0049/SEROCO
First Posted:
Jul 22, 2020
Last Update Posted:
Jan 13, 2021
Last Verified:
Nov 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 13, 2021